Related Experiment Videos
[La Peyronie's disease. Our experience].
G Revelli1, B Marino, F Piccoli
1Divisione di Chirurgia Generale, Regione Piemonte, U.S.L. n. 30, Ospedale Maggiore, Chieri.
Minerva Chirurgica
|January 1, 1990
Summary
This study reviews Peyronie's disease (I.P.P.), highlighting orgotein (SOD) for pain reduction and improved sexual function. For advanced cases, silastic prostheses offer a solution for continued sexual activity and reduced stress.
Area of Science:
- Urology
- Andrology
- Regenerative Medicine
Background:
- Peyronie's disease (I.P.P.) is a condition affecting penile health.
- Understanding its aetiopathogenesis is crucial for effective management.
- Current therapeutic options require careful consideration.
Purpose of the Study:
- To review the aetiopathogenesis of I.P.P.
- To assess diagnostic and therapeutic strategies.
- To evaluate novel medical and surgical interventions.
Main Methods:
- A comprehensive review of existing literature on I.P.P.
- Analysis of diagnostic criteria and imaging techniques.
- Evaluation of pharmacological and surgical treatment outcomes.
Main Results:
- Orgotein, a superoxide dismutase (SOD), shows promise in reducing pain and penile curvature.
- Early intervention with orgotein can improve sexual function.
- Silastic prostheses are effective for advanced or plaque-form I.P.P.
Conclusions:
- Orgotein represents a valuable medical treatment for I.P.P., particularly when initiated early.
- Surgical intervention with prostheses provides a viable solution for intractable cases.
- Both approaches aim to restore sexual function and alleviate associated psychological and familial stress.